Parametrica Management’s West Pharmaceutical WST Stock Holding History

Parametrica Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,885	Closed	-$524K	–	186
2021 Q1	$524K	Buy	1,885 +707	+60%	+$202K	0.25%	75
2020 Q4	$333K	Buy	+1,178	New	+$331K	0.21%	96
2020 Q2	–	Sell	-3,017	Closed	-$459K	–	280
2020 Q1	$459K	Buy	+3,017	New	+$464K	0.46%	44
2019 Q1	–	Sell	-2,728	Closed	-$267K	–	322
2018 Q4	$267K	Sell	2,728 -344	-11%	-$37.3K	0.33%	156
2018 Q3	$379K	Buy	+3,072	New	+$345K	0.83%	25
2017 Q2	–	Sell	-2,785	Closed	-$227K	–	391
2017 Q1	$227K	Sell	2,785 -3,999	-59%	-$334K	0.24%	224
2016 Q4	$575K	Buy	+6,784	New	+$533K	0.57%	54
2016 Q3	–	Sell	-4,539	Closed	-$344K	–	250
2016 Q2	$344K	Buy	+4,539	New	+$330K	0.52%	67
2014 Q1	–	Sell	-4,461	Closed	-$219K	–	133
2013 Q4	$219K	Buy	+4,461	New	+$209K	0.6%	92

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Parametrica Management's WST Position: Q2 2021 in Review

Parametrica Management sold out of West Pharmaceutical (WST) in Q2 2021, closing a stake of 1,885 shares — an estimated $524K sold.

Parametrica Management first reported a position in WST in Q4 2013 and held it in 9 quarters. The position peaked at $575K in Q4 2016. 640 funds tracked by Wall St. Rank hold WST as of Q2 2021.

Parametrica Management reported no remaining West Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Parametrica Management sold 1,885 West Pharmaceutical shares in Q2 2021, an estimated $524K.
Parametrica Management first reported a position in West Pharmaceutical in Q4 2013 and held it in 9 quarters.
Parametrica Management's West Pharmaceutical position peaked at $575K in Q4 2016.
640 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2021.

Based on Parametrica Management's 13F filing for Q2 2021, filed 13 Aug 2021.